Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Artilide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 3/20 | 0.70 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.70 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.70 |
| ▸ | CACNA1F known ✓ | O60840 | 1/20 | 0.70 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.70 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.70 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.70 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.70 |
| ▸ | CACNA1D known ✓ | Q01668 | 1/20 | 0.70 |
| ▸ | CACNA1S known ✓ | Q13698 | 1/20 | 0.70 |
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.70 |
| ▸ | ADRB2 known ✓ | P07550 | 2/20 | 0.46 |
| ▸ | ADRB1 known ✓ | P08588 | 2/20 | 0.46 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.46 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.38 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.38 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.38 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.38 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Artilide SCHEMBL222378 | 0.92 | KCNH2 (0.81) | KCNH2CHRM2SLC6A4DRD3CACNA1F | |
| Artilide SCHEMBL9225647 | 0.92 | KCNH2 (0.81) | KCNH2CHRM2SLC6A4DRD3CACNA1F | |
| Ibutilide SCHEMBL42074 | 0.91 | KCNH2 (0.85) | KCNH2CHRM2SLC6A4DRD3CACNA1F | |
| Ibutilide SCHEMBL42073 | 0.91 | KCNH2 (0.85) | KCNH2CHRM2SLC6A4DRD3CACNA1F | |
| Ibutilide SCHEMBL1649397 | 0.91 | KCNH2 (0.85) | KCNH2CHRM2SLC6A4DRD3CACNA1F | |
| Ibutilide SCHEMBL15540420 | 0.91 | KCNH2 (0.85) | KCNH2CHRM2SLC6A4DRD3CACNA1F | |
| SCHEMBL9220949 | 0.88 | KCNH2 (0.76) | KCNH2CHRM2SLC6A4DRD3CACNA1F | |
| Fumaric Acid SCHEMBL8197898 | 0.85 | ADRA2C (0.72) | KCNH2CHRM2SLC6A4DRD3CACNA1F | |
| Fumaric Acid SCHEMBL8201351 | 0.84 | KCNH2 (0.69) | KCNH2CHRM2SLC6A4DRD3CACNA1F | |
| SCHEMBL9624685 | 0.83 | KCNH2 (0.98) | KCNH2CHRM2SLC6A4DRD3CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 343 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20040229920-A1 | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use | GARVEY DAVID S (US) | 2004-11-18 | — | — | US | claimed |
| US-20020143188-A1 | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use | GARVEY DAVID S (US) | 2002-10-03 | — | — | US | claimed |
| WO-2000067754-A1 | NITROSATED AND NITROSYLATED POTASSIUM CHANNEL ACTIVATORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-11-16 | — | — | WO | claimed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12403090-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250255780-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-08-14 | — | — | US | disclosed |
| WO-2000067754-A1 | NITROSATED AND NITROSYLATED POTASSIUM CHANNEL ACTIVATORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-11-16 | — | — | WO | disclosed |
| WO-2000050020-A2 | USE OF SULFAMATE DERIVATIVES FOR TREATING IMPULSE CONTROL DISORDERS | UNIVERSITY OF CINCINNATI (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0909183-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | Neuromedica, Inc. (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143188-A1 | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use | KCNN3, KCNN1, KCNN2 | KCNH2 15/4885CHRM2 364/4885SLC6A4 261/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | KCNH2 511/4885CHRM2 158/4885SLC6A4 120/4885 |
| US-20040229920-A1 | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use | KCNN3, KCNN1, KCNN2 | KCNH2 15/4885CHRM2 364/4885SLC6A4 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.